Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Expected to Earn Q4 2024 Earnings of $0.10 Per Share

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Stock analysts at Leerink Partnrs upped their Q4 2024 earnings per share estimates for shares of Ironwood Pharmaceuticals in a research note issued on Monday, September 30th. Leerink Partnrs analyst F. Khurshid now forecasts that the biotechnology company will post earnings of $0.10 per share for the quarter, up from their previous estimate of $0.09. Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.24 per share. Leerink Partnrs also issued estimates for Ironwood Pharmaceuticals’ Q3 2025 earnings at $0.05 EPS, Q4 2025 earnings at $0.05 EPS, FY2025 earnings at $0.17 EPS and FY2026 earnings at $0.45 EPS.

IRWD has been the topic of several other research reports. Capital One Financial downgraded Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and cut their price objective for the stock from $12.00 to $4.00 in a report on Thursday, August 8th. Craig Hallum reduced their price target on shares of Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating for the company in a research report on Friday, August 9th. Wells Fargo & Company reduced their price target on shares of Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating for the company in a research report on Friday, August 9th. Leerink Partners initiated coverage on shares of Ironwood Pharmaceuticals in a research report on Monday, September 9th. They issued a “market perform” rating and a $5.00 price target for the company. Finally, StockNews.com raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, July 16th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $12.17.

Ironwood Pharmaceuticals Trading Up 6.0 %

NASDAQ IRWD opened at $4.26 on Tuesday. The stock’s 50-day moving average price is $4.91 and its two-hundred day moving average price is $6.35. The company has a market cap of $666.81 million, a PE ratio of -0.63 and a beta of 0.49. Ironwood Pharmaceuticals has a 1 year low of $3.79 and a 1 year high of $15.70.

Insider Activity at Ironwood Pharmaceuticals

In related news, insider Minardo John sold 9,910 shares of the firm’s stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $4.27, for a total transaction of $42,315.70. Following the transaction, the insider now owns 284,661 shares of the company’s stock, valued at $1,215,502.47. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 12.90% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. grew its holdings in Ironwood Pharmaceuticals by 21.8% during the first quarter. Vanguard Group Inc. now owns 19,521,366 shares of the biotechnology company’s stock valued at $170,031,000 after purchasing an additional 3,487,821 shares during the last quarter. Pacer Advisors Inc. grew its stake in Ironwood Pharmaceuticals by 23.6% in the 2nd quarter. Pacer Advisors Inc. now owns 8,907,639 shares of the biotechnology company’s stock valued at $58,078,000 after buying an additional 1,701,452 shares during the last quarter. Renaissance Technologies LLC grew its stake in Ironwood Pharmaceuticals by 20.7% in the 2nd quarter. Renaissance Technologies LLC now owns 8,571,898 shares of the biotechnology company’s stock valued at $55,889,000 after buying an additional 1,472,097 shares during the last quarter. Armistice Capital LLC lifted its position in Ironwood Pharmaceuticals by 44.4% during the 2nd quarter. Armistice Capital LLC now owns 7,800,000 shares of the biotechnology company’s stock worth $50,856,000 after acquiring an additional 2,400,000 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. boosted its holdings in Ironwood Pharmaceuticals by 40.8% during the first quarter. Jacobs Levy Equity Management Inc. now owns 4,235,580 shares of the biotechnology company’s stock valued at $36,892,000 after acquiring an additional 1,226,377 shares during the period.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.